159 related articles for article (PubMed ID: 30146959)
1. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.
Bhatti T; Lum K; Holland S; Sassman S; Findlay D; Outterson K
J Law Med Ethics; 2018 Jun; 46(1_suppl):59-65. PubMed ID: 30146959
[TBL] [Abstract][Full Text] [Related]
2. Countries mull over incentives for developing antibiotics.
Anderson T
Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
[No Abstract] [Full Text] [Related]
3. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
Brogan DM; Mossialos E
Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
[TBL] [Abstract][Full Text] [Related]
4. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a Market Entry Reward within the United States.
Daniel GW; Schneider M; Lopez MH; McClellan MB
J Law Med Ethics; 2018 Jun; 46(1_suppl):50-58. PubMed ID: 30146957
[TBL] [Abstract][Full Text] [Related]
6. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
Brogan DM; Mossialos E
Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
[TBL] [Abstract][Full Text] [Related]
7. What are the economic barriers of antibiotic R&D and how can we overcome them?
Renwick M; Mossialos E
Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
[No Abstract] [Full Text] [Related]
8. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
[TBL] [Abstract][Full Text] [Related]
9. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
Kesselheim AS; Outterson K
Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
[TBL] [Abstract][Full Text] [Related]
10. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
Savic M; Årdal C
J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
[TBL] [Abstract][Full Text] [Related]
11. Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.
Morel CM; Edwards SE
J Law Med Ethics; 2018 Jun; 46(1_suppl):75-80. PubMed ID: 30146962
[TBL] [Abstract][Full Text] [Related]
12. Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others.
Bettiol E; Hackett J; Harbarth S
J Law Med Ethics; 2018 Jun; 46(1_suppl):5-8. PubMed ID: 30146955
[TBL] [Abstract][Full Text] [Related]
13. Pay drug companies $1bn for each new antibiotic, says report.
Owen J
BMJ; 2016 May; 353():i2863. PubMed ID: 27198868
[No Abstract] [Full Text] [Related]
14. The economics of resistant pathogens and antibiotic innovation.
McKellar MR; Chernew ME; Fendrick AM
Am J Manag Care; 2014 Mar; 20(3):193-7. PubMed ID: 24884749
[No Abstract] [Full Text] [Related]
15. Is the GAIN Act a turning point in new antibiotic discovery?
Brown ED
Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
[TBL] [Abstract][Full Text] [Related]
16. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic research and development: business as usual?
Harbarth S; Theuretzbacher U; Hackett J;
J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
[TBL] [Abstract][Full Text] [Related]
18. Time for a change: addressing R&D and commercialization challenges for antibacterials.
Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial R&D incentives.
Laxminarayan R; Powers JH
Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
[No Abstract] [Full Text] [Related]
20. Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics.
Lum K; Bhatti T; Holland S; Guthrie M; Sassman S
J Law Med Ethics; 2018 Jun; 46(1_suppl):66-74. PubMed ID: 30146960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
